Characteristics Associated with the Choice of First Injectable Therapy Among US Patients With Type 2 Diabetes

Clinical Therapeutics

Volumn 39, Issue 12, 2017, Pages 2399-2408

  Yu, Maria ^a   Mody, Reema ^a   Landó, Laura Fernández ^b   Shui, Amy ^c   Kallenbach, Lee ^c   Slipski, Lukas ^c   de Oliveira, Carolina Piras ^b  

^a ELI LILLY AND COMPANY   (United States)

^b Lilly Corporate Center   (United States)

^c Practice Fusion Inc   (United States)

Author keywords

basal insulin; GLP 1 receptor agonist; real world; type 2 diabetes mellitus

Indexed keywords

ALBIGLUTIDE; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; LIRAGLUTIDE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL FEATURE; DEMOGRAPHY; DIABETIC PATIENT; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; UNITED STATES; AGED; AGONISTS; BLOOD; BODY MASS; CLINICAL PRACTICE; DIABETIC COMPLICATION; INJECTION; ODDS RATIO;

AGED; BODY MASS INDEX; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS; INSULIN; MALE; MIDDLE AGED; ODDS RATIO; PRACTICE PATTERNS, PHYSICIANS'; UNITED STATES;

EID: 85035245810     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2017.11.001     Document Type: Article

References (34)

1. Centers for Disease Control, National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014, U.S. Department of Health and Human Services, Editor. 2014: Atlanta, GA.
2. Alwan, A., Global status report on noncommunicable diseases 2010. 2011, W.H. Organization, Editor.
3. American Diabetes, A. Diagnosis and classification of diabetes mellitus. Diabetes Care 37:Suppl 1 (2014), S81–S90.
4. Standards of Medical Care in Diabetes-2017: Summary of Revisions. Diabetes Care 40:Suppl 1 (2017), S4–S5.
5. Inzucchi, S.E., et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38 (2015), 140–149.
6. Inzucchi, S.E., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35 (2012), 1364–1379.
7. Garber, A.J., et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm—2016 Executive Summary. Endocr Pract 22 (2016), 84–113.
8. Riddle, M.C., et al. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003), 3080–3086.
9. Rosenstock, J., et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 28 (2005), 950–955.
10. Fulcher, G., et al. What happens when patients require intensification from basal insulin? A retrospective audit of clinical practice for the treatment of type 2 diabetes from four Australian centres. Diabetes Res Clin Pract 108 (2015), 405–413.
11. Holman, R.R., et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 361 (2009), 1736–1747.
12. Hermansen, K., Mortensen, L.S., Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 30 (2007), 1127–1142.
13. Ross, S.A., Ballantine, J., Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes. Curr Med Res Opin 29:12 (2013), 1617–1626.
14. Drucker, D.J., Nauck, M.A., The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006), 1696–1705.
15. Koliaki, C., Doupis, J., Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes Ther 2 (2011), 101–121.
16. Blair, H.A., Keating, G.M., Albiglutide: a review of its use in patients with type 2 diabetes mellitus. Drugs 75 (2015), 651–663.
17. Gentilella, R., et al. Exenatide: a review from pharmacology to clinical practice. Diabetes Obes Metab 11 (2009), 544–556.
18. Jendle, J., et al. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab Res Rev 32 (2016), 776–790.
19. Scott, L.J., Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus. Drugs 74 (2014), 2161–2174.
20. Syed, Y.Y., McCormack, P.L., Exenatide extended-release: an updated review of its use in type 2 diabetes mellitus. Drugs 75 (2015), 1141–1152.
21. Fabunmi, R., et al. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Curr Med Res Opin 25 (2009), 777–786.
22. Thayer, S., et al. The INITIATOR study: pilot data on real-world clinical and economic outcomes in US patients with type 2 diabetes initiating injectable therapy. Adv Ther 30 (2013), 1128–1140.
23. Singhal, M., et al. Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes. J Manag Care Spec Pharm 23 (2017), 267–275.
24. Deyo, R.A., Cherkin, D.C., Ciol, M.A., Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45 (1992), 613–619.
25. Young, B.A., et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care 14 (2008), 15–23.
26. Elith, J., Leathwick, J.R., Hastie, T., A working guide to boosted regression trees. J Anim Ecol 77 (2008), 802–813.
27. Greg Ridgeway. Generalized boosted regression models: a guide to the gbm package. 2013 [cited 2017 May 5]; http://cran.r-project.org/web/packages/gbm/gbm.pdf.
28. Astrup, A., et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 36 (2012), 843–854.
29. Umpierrez, G.E., et al. Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment. Diabetes Obes Metab 18 (2016), 615–622.
30. Boehringer Ingelheim Pharmaceuticals, I. Jardiance [US package insert (USPI)] 2016 [cited 2017 May 18]; http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Jardiance/jardiance.pdf.
31. Janssen Pharmaceuticals, I. Invokana [US package insert (USPI)]. 2016 [cited 2017 May 18]; http://www.invokana.com/prescribing-information.pdf.
32. AstraZeneca Farxiga [US package insert (USPI)]. 2016 [cited 2017 May 18]; http://www.azpicentral.com/farxiga/pi_farxiga.pdf#page=1.
33. Alatorre, C., et al. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide. Diabetes Obes Metab 19 (2017), 953–961.
34. Nathan, D.M., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32 (2009), 193–203.